Roth Capital Keeps ImmunoCellular (IMUC) at Neutral; Sidelined Until More ICT-107 Answers Appear
Tweet Send to a Friend
Roth Capital reiterated its Neutral rating and $2 price target on ImmunoCellular Therapeutics (AMEX: IMUC) following the Company's update on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
